CPT® Code 90697

Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use

The CPT® Code 90697 refers to a combination vaccine that includes diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine (DTaP), inactivated poliovirus vaccine (IPV), Haemophilus influenzae type b (Hib) PRP-OMP conjugate vaccine, and hepatitis B vaccine (HepB). This vaccine is specifically formulated for intramuscular use. Vaccines, unlike immune globulins, which offer short-term passive immunity, are designed to provide long-term immunity. They achieve this by exposing the immune system to a modified version of a virus or bacteria, prompting the immune system to produce its own antibodies against the pathogen. The immune system retains a memory of how to generate these antibodies, enabling a quicker response upon subsequent exposure to the same antigen. The components of this combination vaccine serve distinct purposes: Diphtheria toxoid stimulates the immune system to produce antibodies that neutralize the diphtheria toxin, which can cause severe inflammation and damage to the respiratory tract. Tetanus toxoid similarly prompts antibody production against the neurotoxic effects of tetanus, which can lead to painful muscle contractions. The acellular pertussis component, derived from purified antigens of Bordetella pertussis, is less likely to provoke adverse reactions compared to the whole-cell pertussis vaccine and protects against whooping cough, an acute respiratory infection characterized by severe coughing fits. The IPV component protects against poliovirus, which can lead to paralysis by affecting the central nervous system. The Hib vaccine protects against infections caused by H. influenzae type b, which can result in serious conditions such as pneumonia, meningitis, and sepsis. Lastly, the HepB vaccine provides immunity against hepatitis B, a viral infection that can lead to severe liver disease and other serious health complications. It is important to note that this code specifically reports the supply of the DTaP-IPV-Hib-HepB combination vaccine and does not include the administration of the vaccine via intramuscular injection.